How can Biopharma firms innovate beyond the molecule?
The biopharmaceutical industry has joined the digital revolution. AI and machine learning are transforming how medicines are developed. This is driving unprecedented investment, with pharma putting $33 billion into digital R&D in 2021 alone.
This report describes the key success factors for starting on this path. It argues that pharma firms should act now to innovate beyond the molecule if they are to realize maximum returns.
Download the whitepaper to learn: